A seer-medicare based quality score for patients with metastatic upper tract urothelial carcinoma and its association with cost and survival

You have accessJournal of UrologyCME1 Apr 2023MP69-09 A SEER-MEDICARE BASED QUALITY SCORE FOR PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA AND ITS ASSOCIATION WITH COST AND SURVIVAL Daniel D. Joyce, Yong Shan, Courtney A. Stewart, Karim Chamie, Stephen A. Boorjian, Stephen B. Williams, and Vidit Sharma Daniel D. JoyceDaniel D. Joyce More articles by this author , Yong ShanYong Shan More articles by this author , Courtney A. StewartCourtney A. Stewart More articles by this author , Karim ChamieKarim Chamie More articles by this author , Stephen A. BoorjianStephen A. Boorjian More articles by this author , Stephen B. WilliamsStephen B. Williams More articles by this author , and Vidit SharmaVidit Sharma More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003332.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Population-based studies evaluating outcomes exclusively for metastatic upper tract urothelial carcinoma (mUTUC) are sparse and often only capture patients with de novo (synchronous) metastases as opposed to those who progress to metastatic disease (metachronous). We sought to evaluate the outcomes and costs associated with mUTUC and employ a novel methodology to identify both synchronous and metachronous mUTUC patients using claims data. Additionally, we created a guideline-based quality score to improve quality of care in this space. METHODS: Using the SEER-Medicare database we identified all patients aged 66 years and older diagnosed with mUTUC between 2004 and 2012. Achievement of the following quality criteria was assessed: 1) cancer-specific survival greater than 12 months; 2) receipt of systemic therapy; 3) receipt of hospice/palliative care. Kaplan-Meier survival curves and Cox proportional hazard models were used to compare overall survival between quality scores (0 vs. ≥1) and synchronous vs. metachronous mUTUC. Total healthcare and Medicare Part D out-of-pocket costs within two years of diagnosis were evaluated. Regression analyses were performed to assess characteristics associated with quality criteria and total healthcare costs. RESULTS: Of the 1,223 patients identified, 381 (31.2%) and 842 (68.8%) had synchronous and metachronous mUTUC, respectively. At least one quality criterion was met in 40.2% of patients. Notably, only 54 patients (4.4%) received palliative care services. On multivariable analysis, patients with synchronous mUTUC (Odds Ratio [OR] 0.55, 95% CI 0.41–0.72), and at least 3 comorbidities (OR 0.68, 95% CI 0.47–0.98), were less likely to achieve at least one quality criterion. Patients who achieved at least one quality score criterion had longer survival compared with patients who did not meet criteria (HR 0.52, 95% CI 0.46–0.59). Meeting at least one quality criterion was independently associated with increased costs ($94,677, 95% CI 87702–101652 vs. $63575, 95% CI 59598–67552) on multivariable regression analysis. CONCLUSIONS: Less than half of mUTUC patients met at least one quality criterion, and in particular palliative care services were significantly underutilized. Quality score achievement was associated with longer overall survival at a modest increase in total healthcare spending. These findings not only provide guidance for future study of rare diseases using secondary data, but also highlight inadequacies in the current management of mUTUC. Source of Funding: DoD PRCRP. UroGen Pharma © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e967 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Daniel D. Joyce More articles by this author Yong Shan More articles by this author Courtney A. Stewart More articles by this author Karim Chamie More articles by this author Stephen A. Boorjian More articles by this author Stephen B. Williams More articles by this author Vidit Sharma More articles by this author Expand All Advertisement PDF downloadLoading ...